FDA Rebuffs NDA For EpiCept's Ceplene In AML, Asks For Overall Survival Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The design of a requested study to tease out Ceplene's contribution when used in combination with IL-2 was an ethical roadblock for European regulators, who saw no effective comparator and dropped the requirement.